Uncontrolled Epstein-Barr Virus as an Atypical Presentation of Deficiency in ADA2 (DADA2)

[1]  D. Boutboul,et al.  Late-Onset EBV Susceptibility and Refractory Pure Red Cell Aplasia Revealing DADA2 , 2020, Journal of Clinical Immunology.

[2]  Sri V. V. Deevi,et al.  ADA2 deficiency complicated by EBV-driven lymphoproliferative disease , 2020, Clinical immunology.

[3]  S. Holland,et al.  Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. , 2017, Blood.

[4]  J. Dalal,et al.  Refractory Pure Red Cell Aplasia Manifesting as Deficiency of Adenosine Deaminase 2. , 2017, Journal of pediatric hematology/oncology.

[5]  G. Damonte,et al.  ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study , 2017, Annals of the rheumatic diseases.

[6]  A. Zavialov,et al.  Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells , 2017, Cellular and Molecular Life Sciences.

[7]  S. Holland,et al.  Adenosine deaminase type 2 deficiency masquerading as GATA2 deficiency: Successful hematopoietic stem cell transplantation. , 2016, The Journal of allergy and clinical immunology.

[8]  C. Wouters,et al.  Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency , 2015, The Journal of allergy and clinical immunology.

[9]  J. Mullikin,et al.  Early-onset stroke and vasculopathy associated with mutations in ADA2. , 2014, The New England journal of medicine.

[10]  T. Walsh,et al.  Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. , 2014, The New England journal of medicine.